{
    "relation": [
        [
            "",
            "Principal Investigator:",
            "Study Director:",
            "Study Director:",
            "Study Director:",
            "Study Director:"
        ],
        [
            "",
            "David B Price, MD",
            "Dermot Ryan, MBBS",
            "Rupert Jones, MBBS",
            "Eric Bateman, MD",
            "Matt Kearney, MPH"
        ],
        [
            "",
            "Research in Real-Life Ltd",
            "University of Edinburgh",
            "Peninsula College of Medinicne and Dentistry",
            "University of Cape Town",
            "Department of Health, United Kingdom"
        ],
        [
            "",
            "",
            "",
            "",
            "",
            ""
        ]
    ],
    "pageTitle": "Comorbidities and Healthcare Utilisation: Indicators for Improving COPD Diagnosis - Full Text View - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/show/NCT01655667",
    "hasHeader": true,
    "headerPosition": "FIRST_ROW",
    "tableType": "RELATION",
    "tableNum": 6,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042990609.0/warc/CC-MAIN-20150728002310-00187-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 873304731,
    "recordOffset": 873295823,
    "tableOrientation": "HORIZONTAL",
    "TableContextTimeStampAfterTable": "{6277=Subjects aged 40 years or older, with an electronically coded diagnosis of COPD made between 1990 and 2009, a minimum of three years continuous practice data including two years prior to and one year post diagnosis to ensure patients recieved COPD therapy post diagnosis (defined as two or more prescriptions for COPD therapies in the 12 months post diagnosis year 1). COPD therapies included short- and long-acting bronchodilators, inhaled corticosteroids, theophylline and leukotriene receptor antagonists.}",
    "textBeforeTable": "Investigators Department of Health, United Kingdom Research in Real-Life Ltd Sponsors and Collaborators Cambridge, Cambridgeshire, United Kingdom, CB24 3BA Research in Real Life Ltd United Kingdom Please refer to this study by its ClinicalTrials.gov identifier: NCT01655667 Learn About Clinical Studies. Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see \u00a0 Contacts and Locations Less than two prescriptions for COPD therapies in the 12 months post diagnosis year 1. Less than three years continuous practice data including two years prior to Locations",
    "textAfterTable": "\u00a0 More Information No publications provided by Research in Real-Life Ltd Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number): Jones RC, Price D, Ryan D, Sims EJ, von Ziegenweidt J, Mascarenhas L, Burden A, Halpin DM, Winter R, Hill S, Kearney M, Holton K, Moger A, Freeman D, Chisholm A, Bateman ED; Respiratory Effectiveness Group. Opportunities to diagnose chronic obstructive pulmonary disease in routine care in the UK: a retrospective study of a clinical cohort. Lancet Respir Med. 2014 Apr;2(4):267-76. doi: 10.1016/S2213-2600(14)70008-6. Epub 2014 Feb 13. Responsible Party: Shuna Gould, Professor David Price, Research in Real-Life Ltd ClinicalTrials.gov Identifier:",
    "hasKeyColumn": true,
    "keyColumnIndex": 1,
    "headerRowIndex": 0
}